Momenta Pharmaceuticals, Inc. (MNTA) News

Momenta Pharmaceuticals, Inc. (MNTA): $52.48

0.01 (-0.02%)

POWR Rating

Component Grades








Add MNTA to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals




in industry

Filter MNTA News Items

MNTA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest MNTA News From Around the Web

Below are the latest news stories about Momenta Pharmaceuticals Inc that investors may wish to consider to help them evaluate MNTA as an investment opportunity.

Johnson & Johnson to Buy Drug Maker Momenta Pharmaceuticals for $6.5 Billion

It will reportedly be the largest pharma deal to date in 2020, topping Gilead’s $4.9 billion buy of Forty Seven.

Thomasnet | August 25, 2020

Momenta Pharmaceuticals leads healthcare gainers; Eyenovia and Galapagos among losers

Gainers: Momenta Pharmaceuticals (MNTA) +69%. iRhythm Technologies (IRTC) +18%. DarioHealth (DRIO) +16%. Verrica Pharmaceuticals (VRCA) +16%. Avalon GloboCare (AVCO) +15%.Losers: BioMarin Pharmaceutical (BMRN) -33%. Galapagos (GLPG) -23%. Eyenovia (EYEN) -19%. Timber Pharmaceuticals (TMBR) -11%. Scworx (WORX) -10%....

Seeking Alpha | August 19, 2020

J&J buying Momenta in a $6.5B all-cash deal

Johnson & Johnson is buying Momenta Pharmaceuticals in a major all-cash deal. Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and Anjalee Khemlani discuss.

Yahoo Finance | August 19, 2020

Johnson & Johnson to buy Momenta for about US$6.5 billion

Johnson & Johnson said on Wednesday it would buy Momenta Pharmaceuticals Inc for about US$6.5 billion in cash to expand into the area of autoimmune disease treatments.

Channel NewsAsia | August 19, 2020

Momenta Pharmaceuticals' stock rockets after $6.5 billion buyout deal with Johnson & Johnson

Shares of Momenta Pharmaceuticals Inc. undefined rocketed 69% into record territory in premarket trading Wednesday, after the biotechnology company announced…

MarketWatch | August 19, 2020

Momenta Pharmaceuticals EPS misses by $0.07, beats on revenue

Momenta Pharmaceuticals (MNTA): Q2 GAAP EPS of -$0.48 misses by $0.07.Revenue of $6.61M (+27.6% Y/Y) beats by $1.08M.Press Release...

Seeking Alpha | August 10, 2020

Momenta Pharmaceuticals, Inc. 2020 Q2 - Results - Earnings Call Presentation

The following slide deck was published by Momenta Pharmaceuticals, Inc. in conjunction with their 2020 Q2 earnings call....

SA Transcripts on Seeking Alpha | August 10, 2020

Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q2 2020 Results - Earnings Call Transcript

Momenta Pharmaceuticals, Inc. (MNTA) Q2 2020 Results Conference Call August 10, 2020 08:30 AM ET Company Participants Patty Eisenhaur - VP, IR and Corporate Communication Craig Wheeler - President and CEO Young Kwon - Chief Financial and Business Officer Santiago Arroyo - Chief Medical Officer Tony Manning - Chief Scientific...

SA Transcripts on Seeking Alpha | August 10, 2020

Momenta Pharmaceuticals (MNTA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Momenta (MNTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 31, 2020

Will Momenta Pharmaceuticals (NASDAQ:MNTA) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | July 24, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!